Bright Peak Therapeutics (Biotechnology, Health and Wellness) — Funding, Investors & Signals 2026

Bright Peak Therapeutics

Better Biologics Through Chemistry

Founded 2017

Basel, Switzerland 56 employees Series C Total: $232.00M Biotechnology, Health and Wellness +1

Bright Peak Therapeutics, founded in 2017 and headquartered in Switzerland, is revolutionizing biologics with its pioneering approach. The company's portfolio of first-in-class and best-in-class cytokines, aimed at treating cancer and autoimmune diseases, leverages proprietary technology platforms to create bespoke "Bright Peak Immunocytokines" and "duokines". These innovations enable tissue- and cell-specific targeting of the cytokine payload, potentially leading to significantly enhanced efficacy. Additionally, Bright Peak's "off-the-shelf" feature simplifies the conjugation of cytokine payloads with therapeutic antibodies, circumventing the complexities of antibody engineering and cell line development. The company's recent Series C investment of $90.00M on 11 June 2024 was backed by a consortium of prominent investors including RA Capital Management, Venrock, Versant Ventures, Invus, KB Investments, Qatar Investment Authority, Alexandria Venture Investments, Fidelity, Northleaf Capital Partners, and Johnson & Johnson Innovation – JJDC. This significant support underscores the industry's confidence in Bright Peak's innovative approach and its potential to drive meaningful change in patient care. The company's emphasis on innovation and cutting-edge therapies, coupled with its expansion efforts in Basel, Switzerland and Southern California, signals its commitment to becoming a global leader in the biotechnology, health, and life sciences sectors. Bright Peak Therapeutics is poised to shape the future of biologics through the convergence of chemistry and biotechnology.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	••••••	10	•••• ••••	11 Jun 2024
Series B	••••••	7		10 Jun 2021
Series A	••••••	1		28 Jul 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

••••••

•••• ••••

11 Jun 2024

Series B

••••••

10 Jun 2021

Series A

••••••

28 Jul 2020

FAQ About Bright Peak Therapeutics

Better Biologics Through Chemistry

Bright Peak Therapeutics was founded in 2017.

Bright Peak Therapeutics is headquartered in Basel, Switzerland.

Bright Peak Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.

Bright Peak Therapeutics has approximately 56 employees.

Bright Peak Therapeutics has completed 3 funding rounds, raising a total of $232.00M. The latest funding stage is Series C.

Bright Peak Therapeutics offers: Development of multifunctional precision immunotherapies through protein engineering and chemical synthesis.

Top alternatives and competitors to Bright Peak Therapeutics include Harpoon Therapeutics, Synaffix, Silverback Therapeutics, Bright Biologics, Leadartis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Bright Peak Therapeutics and Harpoon Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Bright Peak Therapeutics

General Information

Track Bright Peak Therapeutics

Discover More

About Bright Peak Therapeutics

Services & Products

Target Customers

Funding Rounds & Investors (3)

Latest News

Bright Peak Therapeutics Alternatives & Competitors

FAQ About Bright Peak Therapeutics

Don't just browse. Track.